Rejensa for Dogs in New Zealand: What's in It and What the Research Shows

Rejensa is a veterinary-channel joint chew built around one single active: 1,620 mg of N-butyryl glucosamine, branded Gluco Blu. That one ingredient is the whole story — there is no chondroitin, no MSM, no green-lipped mussel and no collagen in the formula. And while the molecule has genuinely interesting laboratory data behind it, no clinical trial of it in dogs has ever been published in the peer-reviewed literature. For New Zealand owners the label is also written in pounds rather than kilograms, which makes it easy to mis-dose. Here is what the label actually says, what the science does and does not support, converted to metric, and how to decide whether a single-molecule chew is the right call for your dog.

What is Rejensa for dogs?

Rejensa is a soft joint-care chew manufactured exclusively for Phibro Animal Health Corporation (Teaneck, NJ). It is worth clearing up a common mix-up straight away: Rejensa is not a Nutramax product. Nutramax makes Cosequin and Dasuquin; Phibro is a separate company. Rejensa is distributed through veterinary clinics rather than general retail, in 30- and 60-count jars.

The label, ingredient by ingredient

The active panel on the published label is a single line:

The inactive ingredients are caramel powder, chicken digest, chicken meal, cultured skim milk, dried molasses, egg product, glycerin, natural smoke flavour, rice flour, rice bran, salt and tocopherol. Two practical notes from that list that the marketing does not highlight: the chew contains chicken, egg and dairy, which matters if your dog is on a protein-elimination diet for suspected food sensitivity; and xylitol does not appear anywhere on the published ingredient list.

Rejensa dosage by dog weight, in kilograms

The published label gives weight bands in pounds. The kilogram figures below are a straight conversion of those bands — the amounts themselves are the manufacturer's, not ours.

Giant-breed owners should note that last row. If you have a Great Dane, a Mastiff or a Saint Bernard above 54 kg, the label simply stops, and extrapolating a dose yourself is not the right move.

Does Rejensa work? What the research actually shows

This is where an honest answer matters more than a confident one. The molecule and the product need to be judged separately.

The molecule: real laboratory data, all of it non-canine

N-butyryl glucosamine (GlcNBu) is not a marketing rebrand of ordinary glucosamine. It is a chemically distinct analogue, and in cell culture it behaves differently. In neonatal rat chondrocytes, GlcNBu significantly increased type II collagen and aggrecan messenger RNA over six days, an effect not produced by other glucosamine derivatives tested (Journal of Pharmacology and Experimental Therapeutics, 2004; PMID 15240824). In bovine and human chondrocytes, GlcNBu increased cell proliferation and proteoglycan synthesis while plain glucosamine hydrochloride was dose-dependently inhibitory (Journal of Rheumatology, 2005; PMID 16142878). In a rat streptococcal cell-wall arthritis model, oral GlcNBu at 200 mg/kg/day reduced ankle swelling by roughly a third and helped preserve bone architecture (Journal of Rheumatology, 2007; PMID 17309122).

Two caveats belong next to that. First, the same body of work includes a negative result: in osteoblasts from osteoarthritis patients, GlcNBu did not significantly change proliferation or differentiation (Carbohydrate Research, 2005; PMID 15993867). Second, rat pharmacokinetics put oral bioavailability of GlcNBu below 17% (Journal of Pharmacy and Pharmaceutical Sciences, 2006; PMID 17207418) — a figure that sits awkwardly beside "more bioavailable" claims, since no head-to-head absorption study comparing GlcNBu with glucosamine sulfate or hydrochloride has been published in any species.

The product: the "16 days" claim is company data on file

Rejensa's marketing centres on a blinded crossover study in which dogs improved on quality-of-life measures within 16 days while a leading glucosamine product did not. On Phibro's own website, every efficacy claim carries the same footnote: "Data on file. Phibro Animal Health Corporation." A search of the peer-reviewed literature returns no canine clinical trial of GlcNBu at all, and no publication matching that 16-day crossover design.

That does not mean the studies never happened or that the result is false — Phibro does make canine study summaries available to veterinarians. It means they have not been through peer review, the methods and dropout data are not public, and no independent group has been able to reproduce them. For a shopper, the useful translation is: the published evidence chain for Rejensa runs from rat cells to rat models to a commercial dog chew, with the dog step unpublished.

How Rejensa fits into the wider joint-supplement evidence

Zoom out and the picture gets more useful. The largest analysis of the field — a 2022 systematic review and meta-analysis of 72 trials across nine compound categories (International Journal of Molecular Sciences, 2022; PMID 36142319) — reported "an evident clinical analgesic efficacy for omega-3-enriched diets, omega-3 supplements and cannabidiol," a "weak efficacy of collagen," and a "very marked non-effect of chondroitin-glucosamine nutraceuticals," concluding that the latter "should no longer be recommended" for osteoarthritis pain in dogs and cats.

An earlier systematic review reached the same shape of conclusion: strength of evidence was low for every nutraceutical except omega-3 fatty acids in dogs (Journal of Veterinary Internal Medicine, 2012; PMID 22404506). The 2022 AAHA Pain Management Guidelines follow that line, placing non-omega-3 nutritional supplements in tier 3 and stating there is "no evidence to support an analgesic effect of non–omega-3 nutritional supplements," while omega-3s, weight optimisation and exercise sit in tier 1 alongside NSAIDs.

The pattern nobody puts on a label

There is a consistent split in this literature that explains most of the confusion. When a trial measures subjective owner or veterinarian scores, glucosamine-family products often look good — a 2007 trial in The Veterinary Journal (PMID 16647870) found glucosamine/chondroitin improved pain and weight-bearing scores by day 70. When a trial measures objective gait kinetics on a force plate, they generally do not separate from placebo — in a 2023 placebo-controlled study of 75 dogs with hip osteoarthritis (Frontiers in Veterinary Science; PMID 36816197), green-lipped-mussel extract and carprofen both beat placebo on peak vertical force, while the glucosamine/chondroitin arm did not.

Green-lipped mussel will be a familiar name here — the species is farmed in the Marlborough Sounds and around the Coromandel, and it is one of the few joint ingredients with objective force-plate data behind it. That is a genuine point in its favour, and it is one of the actives Rejensa does not contain.

That is the single most useful filter you can apply when reading any joint supplement's evidence page: ask what was measured, and by whom. The same filter is worth carrying into the prescription aisle — our guide to Adequan for dogs applies it to the one injectable joint drug approved by the United States regulator, and finds no published force-plate study there either.

Evidence tiers, ingredient by ingredient

Rejensa vs Cosequin, Dasuquin and multi-active formulas

Rejensa's design philosophy is the opposite of most of the category. Cosequin and Dasuquin build around glucosamine plus chondroitin (with ASU added in Dasuquin). Rejensa strips the formula to one novel molecule at a high milligram count. Broad-spectrum chews go the other way and stack many actives at moderate amounts.

Neither approach is automatically right. A single-molecule product is easy to evaluate — there is one thing to judge — but it also means one mechanism, and if that mechanism does not help your dog, nothing else in the jar will. A broad formula spreads the bet across mechanisms with independent evidence, which is why our own hip and joint chews for dogs combine glucosamine and chondroitin with green-lipped mussel, UC-II collagen, MSM, hyaluronic acid and omega-3 across eighteen named actives rather than hiding amounts inside a proprietary blend. For a wider view of how the leading options compare, our guide to the best joint supplements for dogs works through the same evidence tiers product by product, and the Cosequin for dogs review covers the most common comparison shoppers make.

Buying joint support in New Zealand

Rejensa is a United States veterinary-channel product, and its label, weight bands and marketing are all written for that market. If your New Zealand clinic does not carry it, that is a distribution question rather than a verdict on the formula — but it does mean the practical decision here is usually between what your vet stocks and what you can order directly.

Two things are worth knowing before you order anything from overseas. Prices for a New Zealand order are shown in New Zealand dollars at checkout, and the landed cost matters as much as the shelf price: a cheap jar can arrive with a customs charge attached. Pure Majesty Pets ships free worldwide, delivered duty paid — duties and GST are settled up front, so there is nothing to pay the courier at the door. Our supplements are made in North America in GMP-certified facilities with a certificate of analysis on every batch, and the range holds a rating of about 4.6 out of 5 across roughly 1,085 reviews.

Seasonality is the other local factor. Cool, damp winters tend to make stiffness more obvious in older dogs, which is when most owners start looking — but a joint supplement is judged over 6 to 8 weeks, so starting in the depths of winter means you are assessing it at the hardest time of year. If you are building a routine for an older dog, our senior dog mobility chews and liquid glucosamine for dogs are the two starting points we point owners to most often, and liquid collagen for dogs covers connective tissue, skin and coat from the same daily dose.

Practical notes before you buy

• Protein sensitivities. Chicken, egg and dairy are all in the chew. If your vet has you on an elimination diet, this is a real conflict.
• Giant breeds. No published dose above 54 kg.
• Source material. Neither the label nor Phibro's site discloses what Gluco Blu is derived from, so shellfish-sensitive households cannot rule it in or out from public information — ask your vet.
• It is a supplement, not analgesia. The label itself says it may be used alongside prescribed joint medication. If your dog is in pain now, a chew is not the tool; talk to your veterinarian about tier 1 options.
• Accidental over-ingestion is the real safety issue. Glucosamine-family products have a wide margin, and most reported problems are gastrointestinal — but dogs eating a whole jar is a documented emergency-line scenario. Store the jar out of reach.
• Give it a fair trial window. Joint supplements are judged over 6–8 weeks of consistent daily use, not over a good week or a bad one. If you want the mechanics of dosing by weight, our guide to glucosamine for dogs lays it out, and glucosamine chews for dogs covers what separates a well-made chew from a padded one.

When to call your vet instead of reaching for a chew

No supplement is the right first response to any of these. Book an appointment — or an emergency visit — if your dog shows:

• Sudden refusal to bear weight on a limb
• A joint that is hot, swollen or visibly enlarged
• Lameness after a fall, a jump or a car incident
• Yelping when a specific area is touched
• Fever alongside limping
• Rapid-onset hind-limb weakness or dragging of the paws

These point toward injury, infection, immune-mediated disease or neurological problems — none of which respond to a joint chew, and several of which get worse while you wait to see if one works.

Frequently asked questions

Is Rejensa made by Nutramax?

No. Rejensa is manufactured exclusively for Phibro Animal Health Corporation. Nutramax is the company behind Cosequin and Dasuquin — a different manufacturer with different formulas.

Is Rejensa clinically proven in dogs?

Not in the peer-reviewed sense. The published research on N-butyryl glucosamine is in cell culture and rodent models; the canine crossover study Phibro cites is company data on file and has not been published or independently reproduced.

How long does Rejensa take to work?

Phibro markets improvement within 16 days based on its internal study. Independently, veterinary practice generally judges any joint supplement over roughly 6 to 8 weeks of consistent daily use, which is the timeline most published canine trials run on.

Can Rejensa be given with NSAIDs or other joint medication?

The label states it may be used alongside prescribed joint medications or on its own. Because dosing and monitoring of prescription analgesia is your veterinarian's call, confirm any combination with them first rather than stacking products at home.

What has the strongest evidence for canine joint health?

Omega-3 EPA/DHA, by a clear margin — it is the only nutraceutical both major systematic reviews singled out positively, and the 2022 AAHA guidelines place it in tier 1 alongside weight management and exercise. Green-lipped mussel and UC-II collagen sit at a moderate tier.

How do I dose a Rejensa chew if my dog's weight is in kilograms?

Convert first, then read the band: up to 13 kg is half a chew, 13 to 27 kg is one chew, 27 to 40 kg is one and a half, and 41 to 54 kg is two. Above 54 kg the label publishes no amount, so ask your veterinarian rather than scaling it yourself.

Does Pure Majesty Pets deliver to New Zealand?

Yes. Shipping is free worldwide and delivered duty paid, so duties and GST are settled before dispatch and there is nothing to pay the courier on arrival. Orders are priced in New Zealand dollars at checkout.

References

1. Rejensa Supplemental Joint Care Chew for Dogs — published label and administration amounts, manufactured exclusively for Phibro Animal Health Corporation (Drugs.com veterinary monograph, DVMetrics/Animalytix; and rejensa.com).
2. Anastassiades T, et al. N-butyryl glucosamine increases matrix gene expression by chondrocytes. J Pharmacol Exp Ther. 2004 (PMID 15240824).
3. Effects of N-butyryl glucosamine on chondrocyte proliferation and proteoglycan synthesis. J Rheumatol. 2005 (PMID 16142878).
4. N-butyryl glucosamine and osteoblasts from osteoarthritis patients. Carbohydr Res. 2005 (PMID 15993867).
5. Pharmacokinetics of N-butyryl glucosamine in rats. J Pharm Pharm Sci. 2006 — oral bioavailability below 17% (PMID 17207418).
6. N-butyryl glucosamine in the streptococcal cell-wall model of arthritis. J Rheumatol. 2007 (PMID 17309122).
7. Barbeau-Grégoire M, Otis C, Cournoyer A, et al. A 2022 systematic review and meta-analysis of enriched therapeutic diets and nutraceuticals in canine and feline osteoarthritis. Int J Mol Sci. 2022;23(18):10384 (PMID 36142319).
8. Vandeweerd JM, Coisnon C, Clegg P, et al. Systematic review of efficacy of nutraceuticals to alleviate clinical signs of osteoarthritis. J Vet Intern Med. 2012;26(3):448-456 (PMID 22404506).
9. McCarthy G, O'Donovan J, Jones B, et al. Randomised double-blind, positive-controlled trial of glucosamine/chondroitin sulfate in dogs with osteoarthritis. Vet J. 2007;174(1):54-61 (PMID 16647870).
10. Kampa N, Kaenkangploo D, Jitpean S, et al. Effectiveness of glucosamine and chondroitin sulfate, marine-based fatty acid compounds (PCSO-524 and EAB-277), and carprofen for dogs with hip osteoarthritis. Front Vet Sci. 2023;10:1033188 (PMID 36816197).
11. Rialland P, Bichot S, Lussier B, et al. Effect of a diet enriched with green-lipped mussel on pain behaviour and functioning in dogs with clinical osteoarthritis. Can J Vet Res. 2013;77(1):66-74 (PMID 23814358).
12. Gupta RC, Canerdy TD, Lindley J, et al. Comparative therapeutic efficacy and safety of type-II collagen, glucosamine and chondroitin in arthritic dogs. J Anim Physiol Anim Nutr. 2012;96(5):770-777 (PMID 21623931); D'Altilio M, et al. Toxicol Mech Methods. 2007;17(4):189-196 (PMID 20020968); DeParle LA, et al. J Vet Pharmacol Ther. 2005;28(4):385-390 (PMID 16050819).
13. Comblain F, Barthélémy N, Lefèbvre M, et al. A randomized, double-blind, placebo-controlled study of a curcuminoid-based supplement in dogs with osteoarthritis. BMC Vet Res. 2017;13(1):395 (PMID 29262825).
14. 2022 AAHA Pain Management Guidelines for Dogs and Cats — tiered treatment recommendations and nutritional supplement placement.

This article is educational and is not veterinary advice. Pure Majesty Pets is not affiliated with Phibro Animal Health Corporation or Nutramax Laboratories; Rejensa, Gluco Blu, Cosequin and Dasuquin are trademarks of their respective owners. These statements have not been evaluated by any medicines or food-safety regulator. Our products are not intended to diagnose, treat, cure or prevent any disease. Always consult your veterinarian before starting, stopping or combining supplements, particularly for a dog on prescription medication.